NCT00001044View on ClinicalTrials.gov

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 1995

Conditions

HIV Infections

Interventions

BIOLOGICAL

Aluminum hydroxide

BIOLOGICAL

QS-21

BIOLOGICAL

rgp120/HIV-1MN

Trial Locations (4)

14642

Univ. of Rochester AVEG, Rochester

15261

JHU AVEG, Pittsburgh

98144

UW - Seattle AVEG, Seattle

63104-1004

St. Louis Univ. School of Medicine AVEG, St Louis

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001044 - A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults. | Biotech Hunter | Biotech Hunter